Value Investing News

With proxy season in full throttle this past week, many of the most heated shareholder activist battles experienced major developments. The biggest activist hedge fund winners of the week were Steel Partners, Carl Icahn and Eastbourne Capital Management, while the biggest losers were Bill Ackman of Pershing Square and Millbrook Capital.

There has been a lot of strong recommendations around biotech lately on Contrarian Profits. Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.

If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…

I’ve been doing more research on Lampert by looking through some old newspaper articles. I’ve gleaned the following by reading a few older articles on Eddie Lampert, specifically a 1995 Washington Post article.

The biotech industry has failed in its attempt to function as a science-based business

Followers of the sector know very well that biotech stocks have traditionally traded at premiums to their big pharma counterparts, mainly due to the fact that they tend to be smaller, and therefore one big product breakthrough can have a dramatic effect on the company, and fuel substantially higher earnings growth. It appears in today's market, however, that the two subsets of healthcare have converged as far as valuations go. As a result, I think there are opportunities for investors to capitalize.